According to GlobalData’s medical device pipeline database, 34 IgE Allergy Blood Tests devices are in various stages of development globally. GlobalData’s report IgE Allergy Blood Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 20 are in active development, while the remaining 14 are in an inactive stage of development. There are eight products in the early stages of development, and the remaining 12 are in the late stages of development.

IgE allergy blood tests measure the total concentration of immunoglobulin E (IgE) or the amount of IgE antibodies to a specific allergen in a serum/blood sample. These two types of tests are the total IgE test and the specific IgE test. A total IgE test helps to determine whether the patient is suffering from an allergic condition or hypersensitivity while a specific IgE test helps to determine the causative allergen for the patient’s allergic symptoms. The IgE allergy blood tests performed using rapid and non-rapid test panels or kits are covered in this segment.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed IgE Allergy Blood Tests pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of IgE Allergy Blood Tests devices. Overall, most of these IgE Allergy Blood Tests pipeline devices are being developed by private entities.

Key players involved in the active development of IgE Allergy Blood Tests include Stanford University, Stanford University, SpinChip Diagnostics, Amerimmune, EUROIMMUN US, Fondation Lenval, G Medical Innovations, Guangzhou Wondfo Biotech, Kenota and King's College London.

For a complete picture of the developmental pipeline for IgE Allergy Blood Tests devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.